ijms-logo

Journal Browser

Journal Browser

Unlocking the Future of Muscle Disease Treatment: Advancements in Gene Therapy, Antisense Therapeutics and Cutting-Edge Pharmacological Strategies

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 20 October 2024 | Viewed by 687

Special Issue Editors


E-Mail Website
Guest Editor
Royal Holloway, University of London, Egham Hill, TW20 0EX Egham, Surrey, UK
Interests: facioscapuloperoneal muscular dystrophy; duchenne muscular dystrophy; gene therapy; antisense therapeutics; pharmacological treatments
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Royal Holloway, University of London, Egham Hill, TW20 0EX Egham, Surrey, UK
Interests: oculopharyngeal muscular dystrophy; duchenne muscular dystrophy; gene therapy; antisense therapeutics; pharmacological treatments

Special Issue Information

Dear Colleagues,

Muscle disorders, including muscular dystrophy and various neuromuscular diseases, are remarkably heterogenic in terms of genetic defects, pathophysiology, and the age of onset. Unfortunately, effective treatments for these disorders have been elusive, principally due to their rarity and the necessity of often mutation-specific approaches and tailored therapies. However, in recent years, we have witnessed the emergence of novel therapies, such as gene therapy, antisense therapeutics, and pharmacological approaches. These breakthroughs have shown promise for the treatment of diseases like Duchenne muscular dystrophy and spinal muscular atrophy and ongoing advancements in the development of treatments for myotubular myopathy or limb girdle muscular dystrophy. These encouraging advancements demonstrate the feasibility of developing treatments for severe and complex muscle diseases using new tools and models and via collaboration between preclinical research laboratories and industries.

In light of these remarkable advancements, we invite scholars to contribute to our Special Issue on “Unlocking the Future of Muscle Disease Treatment: Advancements in Gene Therapy, Antisense Therapeutics and Cutting-Edge Pharmacological Strategies”. We encourage the submission of manuscripts describing basic and translational research studies. We aim to provide the latest insights into the development of innovative methodologies, including in silico and bioinformatics approaches, as well as advancements in in vitro and in vivo models. Ultimately, this Special Issue seeks to shed light on the progress and potential of innovative therapeutic strategies for the treatment of muscular diseases.

Dr. Ngoc B. Lu-Nguyen
Dr. Alberto Malerba
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • muscle disease
  • antisense therapeutics
  • gene therapy
  • pharmacological approach
  • bioinformatic tools
  • cellular models
  • animal models

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

19 pages, 2600 KiB  
Review
Limb Girdle Muscular Dystrophy Type 2B (LGMD2B): Diagnosis and Therapeutic Possibilities
by Bal Hari Poudel, Sue Fletcher, Steve D. Wilton and May Aung-Htut
Int. J. Mol. Sci. 2024, 25(11), 5572; https://doi.org/10.3390/ijms25115572 - 21 May 2024
Viewed by 399
Abstract
Dysferlin is a large transmembrane protein involved in critical cellular processes including membrane repair and vesicle fusion. Mutations in the dysferlin gene (DYSF) can result in rare forms of muscular dystrophy; Miyoshi myopathy; limb girdle muscular dystrophy type 2B (LGMD2B); and [...] Read more.
Dysferlin is a large transmembrane protein involved in critical cellular processes including membrane repair and vesicle fusion. Mutations in the dysferlin gene (DYSF) can result in rare forms of muscular dystrophy; Miyoshi myopathy; limb girdle muscular dystrophy type 2B (LGMD2B); and distal myopathy. These conditions are collectively known as dysferlinopathies and are caused by more than 600 mutations that have been identified across the DYSF gene to date. In this review, we discuss the key molecular and clinical features of LGMD2B, the causative gene DYSF, and the associated dysferlin protein structure. We also provide an update on current approaches to LGMD2B diagnosis and advances in drug development, including splice switching antisense oligonucleotides. We give a brief update on clinical trials involving adeno-associated viral gene therapy and the current progress on CRISPR/Cas9 mediated therapy for LGMD2B, and then conclude by discussing the prospects of antisense oligomer-based intervention to treat selected mutations causing dysferlinopathies. Full article
Show Figures

Figure 1

Back to TopTop